Neuland Laboratories Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Neuland Laboratories wird ein jährliches Gewinn- und Umsatzwachstum von 18.6% bzw. 14.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 18.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 24.4% betragen.
Wichtige Informationen
18.6%
Wachstumsrate der Gewinne
18.44%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 18.3% |
| Wachstumsrate der Einnahmen | 14.5% |
| Zukünftige Eigenkapitalrendite | 24.45% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 06 Aug 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrative-Update • Aug 20
524558: Capacity Expansion And Transdermal CDMO Mandates Will Shape Measured Future Outlook
Analysts have raised their fair value estimate for Neuland Laboratories from ₹22,784.50 to ₹24,334.75, citing updated assumptions for revenue growth, profit margins and future P/E levels. What’s in the News for Neuland Laboratories Board meeting scheduled for 5 August 2026 at 10:00 IST to review unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 and to consider capacity expansion at Unit 1 in Telangana.Narrative-Update • Aug 06
524558: Capacity Plans And Transdermal CDMO Work Will Shape Balanced Future Outlook
Analysts have raised their price target on Neuland Laboratories from ₹20,972 to ₹22,784.50, citing updated assumptions that include a slightly lower discount rate, moderated revenue growth expectations, and a higher profit margin outlook alongside a broadly steady future P/E. What’s in the News for Neuland Laboratories A board meeting is scheduled for August 5, 2026 at 10:00 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.Narrative-Update • Jun 13
524558: New Leadership And Transdermal CDMO Work Will Support Future Upside Potential
Analysts have kept their fair value estimate for Neuland Laboratories steady at ₹20,972, with only marginal tweaks to long term growth, profit margin and future P/E assumptions. As a result, the overall price target remains unchanged.Narrative-Update • May 30
524558: New CEO And CDMO Focus Will Support Future Upside Potential
Analysts now peg Neuland Laboratories' fair value at ₹20,972, compared with the previous ₹18,852.75, citing updates to long term revenue growth, profit margin assumptions, and a higher future P/E multiple in their models. What's in the News A board meeting is scheduled for May 12, 2026 at 14:15 IST to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for FY 2025-26, along with other matters (Key Developments).Narrative-Update • May 12
524558: Leadership Transition And CDMO Focus Will Shape Balanced Future Potential
Analysts have trimmed their fair value estimate for Neuland Laboratories slightly from ₹18,865.25 to ₹18,852.75. This reflects small adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E multiples.Narrative-Update • Apr 20
524558: Leadership Transition And Peptide Collaboration Will Support Future Upside Potential
Analysts have kept their fair value estimate for Neuland Laboratories steady at ₹18,865.25, reflecting unchanged views on discount rate, revenue growth, profit margin, and future P/E assumptions that underpin their price target rationale. What's in the News Neuland Laboratories plans a leadership transition, with Saharsh Davuluri set to become Chief Executive Officer from 01 April 2026.Narrative-Update • Apr 04
524558: Phase 2 Peptide Design Progress Will Support Future Upside Potential
Analysts have maintained their price target for Neuland Laboratories at ₹18,865.25, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. This signals that the latest review did not alter their core outlook on the stock.Narrative-Update • Mar 20
524558: Phase 2 Peptide Progress And 2026 Board Meeting Will Support Upside Potential
Analysts have kept their fair value estimate for Neuland Laboratories steady at ₹18,865.25. This reflects unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E expectations.Narrative-Update • Mar 05
524558: Peptide Partnership Progress And Upcoming Results Date Will Support Future Upside Potential
Analysts have maintained their fair value estimate for Neuland Laboratories at ₹18,865.25 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E. As a result, this narrative update focuses on reaffirmed conviction rather than a change in the price target.Narrative-Update • Feb 19
524558: New R&D Center And Peptide Partnership Will Support Future Upside Potential
Analysts have revised their price target for Neuland Laboratories from ₹20,659 to ₹18,865, reflecting updates to their model that now factors in adjusted assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News LIR Life Sciences has started Project Phase 2 peptide design work with Neuland Laboratories, focusing on next generation cell penetrating peptides for its transdermal delivery platform, following completion of Phase 1 synthesis work (Product related announcement).Narrative-Update • Feb 05
524558: New R&D Center Will Support Future Upside Potential
Analysts have kept their price target for Neuland Laboratories unchanged at ₹20,659, citing consistent assumptions on discount rate, revenue growth, profit margin and future P/E to support their view. What's in the News Board meeting scheduled for February 9, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Board Meeting).Narrative-Update • Jan 21
524558: New R&D Center And Peptide Partnership Will Drive Future Upside
Analysts have trimmed their fair value estimate for Neuland Laboratories from ₹20,884 to ₹20,659, citing slightly adjusted views on revenue growth, profit margins and future P/E assumptions while keeping the discount rate unchanged. What's in the News LIR Life Sciences Corp.Narrative-Update • Jan 06
524558: New R&D Center Capex Will Support Future Upside Potential
Analysts have kept their fair value estimate for Neuland Laboratories unchanged at ₹20,884. This steady view is supported by consistent assumptions on discount rate, revenue growth, profit margin and future P/E.Narrative-Update • Dec 15
524558: New R&D Center Will Drive Future Upside Potential
Narrative Update on Neuland Laboratories Analysts have modestly revised their price target on Neuland Laboratories with a slight adjustment that reflects largely unchanged assumptions around fair value at ₹20,884, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News The board will consider capital expenditure of INR 1,890 million for establishing a new Research and Development Center at the meeting scheduled on November 28, 2025 (Board Meeting).Narrative-Update • Dec 01
524558: R&D Center and Leadership Changes Will Unlock Upside Potential
Analysts have maintained their price target for Neuland Laboratories at ₹20,884, citing consistent estimates for future revenue growth and profit margin projections. What's in the News A Board Meeting is scheduled for November 28, 2025 to approve and consider a capital expenditure of INR 1,890 million for setting up a Research & Development (R&D) Center.Narrative-Update • Nov 17
524558: Executive Leadership Changes Will Drive Future Upside Potential
Analysts have raised their fair value estimate for Neuland Laboratories from ₹17,494.50 to ₹20,884.00. They cite updated assumptions about growth and profitability, despite modest adjustments to revenue growth and profit margin forecasts.Narrative-Update • Nov 03
524558: Leadership Changes And Board Decisions Will Shape The Next Phase
Analysts have raised their price target for Neuland Laboratories from ₹16,375 to ₹17,494.50. This change reflects updated expectations based on modest adjustments in forecasted revenue growth, profit margin, and valuation multiples.Narrative-Update • Sep 05
Manufacturing Expansion And Peptide Expertise Will Unlock Future Opportunities
Neuland Laboratories’ target price has been revised upward as a result of a marked increase in its forecast P/E ratio despite a significant decline in net profit margin, now reflecting a new consensus of ₹16,375. What's in the News Special/Extraordinary Shareholders Meeting to be conducted via postal ballot.
Neues Narrative • Feb 24
Ongoing Capacity Expansions In CDMO And Specialty GDS Set To Strengthen Future Prospects
New facilities and capacity expansion will drive revenue growth and improve operational efficiency by FY '26.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2029 | 34,928 | 8,532 | 6,012 | N/A | 3 |
| 3/31/2028 | 29,266 | 6,265 | 4,045 | N/A | 5 |
| 3/31/2027 | 24,435 | 4,798 | 4,466 | N/A | 5 |
| 6/30/2026 | 23,718 | 4,978 | N/A | N/A | N/A |
| 3/31/2026 | 20,230 | 3,640 | -505 | 3,467 | N/A |
| 12/31/2025 | 15,751 | 1,791 | N/A | N/A | N/A |
| 9/30/2025 | 15,334 | 2,401 | -1,425 | 1,312 | N/A |
| 6/30/2025 | 13,300 | 1,761 | N/A | N/A | N/A |
| 3/31/2025 | 14,768 | 2,601 | 1,109 | 3,174 | N/A |
| 12/31/2024 | 15,335 | 2,999 | N/A | N/A | N/A |
| 9/30/2024 | 15,283 | 2,797 | 413 | 2,457 | N/A |
| 6/30/2024 | 16,352 | 3,361 | N/A | N/A | N/A |
| 3/31/2024 | 15,586 | 3,001 | 1,175 | 2,612 | N/A |
| 12/31/2023 | 15,809 | 3,171 | N/A | N/A | N/A |
| 9/30/2023 | 14,574 | 2,662 | 2,444 | 3,192 | N/A |
| 6/30/2023 | 13,333 | 2,154 | N/A | N/A | N/A |
| 3/31/2023 | 11,915 | 1,635 | 1,711 | 2,372 | N/A |
| 12/31/2022 | 10,406 | 1,008 | N/A | N/A | N/A |
| 9/30/2022 | 10,078 | 831 | 341 | 1,070 | N/A |
| 6/30/2022 | 9,720 | 651 | N/A | N/A | N/A |
| 3/31/2022 | 9,517 | 638 | -373 | 604 | N/A |
| 12/31/2021 | 9,400 | 593 | N/A | N/A | N/A |
| 9/30/2021 | 9,489 | 731 | 359 | 1,437 | N/A |
| 6/30/2021 | 9,324 | 742 | N/A | N/A | N/A |
| 3/31/2021 | 9,370 | 806 | 840 | 1,894 | N/A |
| 12/31/2020 | 8,852 | 540 | N/A | N/A | N/A |
| 9/30/2020 | 8,436 | 384 | 96 | 887 | N/A |
| 6/30/2020 | 7,884 | 257 | N/A | N/A | N/A |
| 3/31/2020 | 7,640 | 162 | N/A | 573 | N/A |
| 12/31/2019 | 7,443 | 321 | N/A | N/A | N/A |
| 9/30/2019 | 7,120 | 257 | N/A | 899 | N/A |
| 6/30/2019 | 6,945 | 216 | N/A | N/A | N/A |
| 3/31/2019 | 6,675 | 164 | N/A | 699 | N/A |
| 3/31/2018 | 5,284 | 121 | N/A | 113 | N/A |
| 3/31/2017 | 5,789 | 469 | N/A | 387 | N/A |
| 3/31/2016 | 5,100 | 273 | N/A | 448 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 524558Das prognostizierte Gewinnwachstum (18.6% pro Jahr) liegt über der Sparquote (6.9%).
Ertrag vs. Markt: 524558Die Erträge des Unternehmens (18.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (16.8% pro Jahr).
Hohe Wachstumserträge: 524558Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: 524558Die Einnahmen des Unternehmens (14.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (11.2% pro Jahr).
Hohe Wachstumseinnahmen: 524558Die Einnahmen des Unternehmens (14.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 524558Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (24.4%)
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/24 07:44 |
| Aktienkurs zum Tagesende | 2026/08/21 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Neuland Laboratories Limited wird von 9 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Srivathsan Ramachandran | Avendus Spark |
| Kameswari V. S. Chavali | FirstCall Research |